nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2C18—prostate cancer	0.362	0.778	CbGaD
Vilazodone—CYP3A4—prostate cancer	0.103	0.222	CbGaD
Vilazodone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0477	0.154	CbGbCtD
Vilazodone—CYP2D6—Bicalutamide—prostate cancer	0.0394	0.128	CbGbCtD
Vilazodone—CYP2D6—Abiraterone—prostate cancer	0.0326	0.106	CbGbCtD
Vilazodone—CYP3A4—Bicalutamide—prostate cancer	0.025	0.0811	CbGbCtD
Vilazodone—CYP3A4—Estramustine—prostate cancer	0.0233	0.0754	CbGbCtD
Vilazodone—CYP3A4—Abiraterone—prostate cancer	0.0208	0.0672	CbGbCtD
Vilazodone—CYP3A4—Flutamide—prostate cancer	0.0208	0.0672	CbGbCtD
Vilazodone—CYP3A4—Cabazitaxel—prostate cancer	0.0154	0.0497	CbGbCtD
Vilazodone—CYP3A4—Estrone—prostate cancer	0.015	0.0486	CbGbCtD
Vilazodone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0134	0.0433	CbGbCtD
Vilazodone—CYP3A4—Conjugated Estrogens—prostate cancer	0.00982	0.0318	CbGbCtD
Vilazodone—CYP3A4—Mitoxantrone—prostate cancer	0.00892	0.0289	CbGbCtD
Vilazodone—CYP3A4—Estradiol—prostate cancer	0.00862	0.0279	CbGbCtD
Vilazodone—CYP3A4—Prednisone—prostate cancer	0.00741	0.024	CbGbCtD
Vilazodone—CYP2D6—Doxorubicin—prostate cancer	0.00604	0.0196	CbGbCtD
Vilazodone—CYP3A4—Etoposide—prostate cancer	0.00563	0.0182	CbGbCtD
Vilazodone—CYP3A4—Docetaxel—prostate cancer	0.00515	0.0167	CbGbCtD
Vilazodone—CYP3A4—Doxorubicin—prostate cancer	0.00384	0.0124	CbGbCtD
Vilazodone—Aripiprazole—CYP3A5—prostate cancer	0.000416	0.35	CrCbGaD
Vilazodone—Trazodone—CYP3A5—prostate cancer	0.000414	0.348	CrCbGaD
Vilazodone—Tremor—Estradiol—prostate cancer	0.000189	0.00139	CcSEcCtD
Vilazodone—Breast disorder—Capecitabine—prostate cancer	0.000189	0.00138	CcSEcCtD
Vilazodone—Insomnia—Goserelin—prostate cancer	0.000188	0.00138	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	0.000187	0.00137	CcSEcCtD
Vilazodone—Paraesthesia—Goserelin—prostate cancer	0.000186	0.00137	CcSEcCtD
Vilazodone—Insomnia—Conjugated Estrogens—prostate cancer	0.000186	0.00136	CcSEcCtD
Vilazodone—Agitation—Estradiol—prostate cancer	0.000185	0.00136	CcSEcCtD
Vilazodone—Dry eye—Epirubicin—prostate cancer	0.000185	0.00136	CcSEcCtD
Vilazodone—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000185	0.00135	CcSEcCtD
Vilazodone—Somnolence—Goserelin—prostate cancer	0.000185	0.00135	CcSEcCtD
Vilazodone—Dysgeusia—Mitoxantrone—prostate cancer	0.000184	0.00135	CcSEcCtD
Vilazodone—Abnormal dreams—Doxorubicin—prostate cancer	0.000183	0.00134	CcSEcCtD
Vilazodone—Somnolence—Conjugated Estrogens—prostate cancer	0.000183	0.00134	CcSEcCtD
Vilazodone—Dyspepsia—Goserelin—prostate cancer	0.000183	0.00134	CcSEcCtD
Vilazodone—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000181	0.00133	CcSEcCtD
Vilazodone—Asthenia—Ethinyl Estradiol—prostate cancer	0.000181	0.00133	CcSEcCtD
Vilazodone—Decreased appetite—Goserelin—prostate cancer	0.00018	0.00132	CcSEcCtD
Vilazodone—Aripiprazole—CYP3A4—prostate cancer	0.00018	0.151	CrCbGaD
Vilazodone—Trazodone—CYP3A4—prostate cancer	0.000179	0.151	CrCbGaD
Vilazodone—Fatigue—Goserelin—prostate cancer	0.000179	0.00131	CcSEcCtD
Vilazodone—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000179	0.00131	CcSEcCtD
Vilazodone—Palpitations—Estradiol—prostate cancer	0.000178	0.00131	CcSEcCtD
Vilazodone—Irritability—Prednisone—prostate cancer	0.000177	0.0013	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000177	0.0013	CcSEcCtD
Vilazodone—Fatigue—Conjugated Estrogens—prostate cancer	0.000177	0.0013	CcSEcCtD
Vilazodone—Nausea—Bicalutamide—prostate cancer	0.000177	0.0013	CcSEcCtD
Vilazodone—Vision blurred—Mitoxantrone—prostate cancer	0.000177	0.0013	CcSEcCtD
Vilazodone—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000173	0.00127	CcSEcCtD
Vilazodone—Arthralgia—Estradiol—prostate cancer	0.000172	0.00126	CcSEcCtD
Vilazodone—Dry eye—Doxorubicin—prostate cancer	0.000171	0.00126	CcSEcCtD
Vilazodone—Feeling abnormal—Goserelin—prostate cancer	0.000171	0.00125	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.00017	0.00125	CcSEcCtD
Vilazodone—Dry mouth—Estradiol—prostate cancer	0.000168	0.00123	CcSEcCtD
Vilazodone—Eye disorder—Etoposide—prostate cancer	0.000168	0.00123	CcSEcCtD
Vilazodone—Dizziness—Ethinyl Estradiol—prostate cancer	0.000167	0.00122	CcSEcCtD
Vilazodone—Cardiac disorder—Etoposide—prostate cancer	0.000167	0.00122	CcSEcCtD
Vilazodone—Convulsion—Mitoxantrone—prostate cancer	0.000163	0.00119	CcSEcCtD
Vilazodone—Nervous system disorder—Estradiol—prostate cancer	0.000161	0.00118	CcSEcCtD
Vilazodone—Vomiting—Ethinyl Estradiol—prostate cancer	0.00016	0.00118	CcSEcCtD
Vilazodone—Arthralgia—Mitoxantrone—prostate cancer	0.00016	0.00117	CcSEcCtD
Vilazodone—Skin disorder—Estradiol—prostate cancer	0.00016	0.00117	CcSEcCtD
Vilazodone—Hyperhidrosis—Estradiol—prostate cancer	0.000159	0.00117	CcSEcCtD
Vilazodone—Increased appetite—Epirubicin—prostate cancer	0.000155	0.00114	CcSEcCtD
Vilazodone—Dysgeusia—Etoposide—prostate cancer	0.000153	0.00112	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Estradiol—prostate cancer	0.00015	0.0011	CcSEcCtD
Vilazodone—Nausea—Ethinyl Estradiol—prostate cancer	0.00015	0.0011	CcSEcCtD
Vilazodone—Asthenia—Goserelin—prostate cancer	0.000149	0.00109	CcSEcCtD
Vilazodone—Skin disorder—Mitoxantrone—prostate cancer	0.000149	0.00109	CcSEcCtD
Vilazodone—Insomnia—Estradiol—prostate cancer	0.000149	0.00109	CcSEcCtD
Vilazodone—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000148	0.00109	CcSEcCtD
Vilazodone—Erectile dysfunction—Prednisone—prostate cancer	0.000148	0.00109	CcSEcCtD
Vilazodone—Paraesthesia—Estradiol—prostate cancer	0.000148	0.00108	CcSEcCtD
Vilazodone—Asthenia—Conjugated Estrogens—prostate cancer	0.000148	0.00108	CcSEcCtD
Vilazodone—Connective tissue disorder—Docetaxel—prostate cancer	0.000147	0.00108	CcSEcCtD
Vilazodone—Somnolence—Estradiol—prostate cancer	0.000146	0.00107	CcSEcCtD
Vilazodone—Hyponatraemia—Epirubicin—prostate cancer	0.000146	0.00107	CcSEcCtD
Vilazodone—Dyspepsia—Estradiol—prostate cancer	0.000145	0.00106	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—prostate cancer	0.000143	0.00105	CcSEcCtD
Vilazodone—Migraine—Epirubicin—prostate cancer	0.000143	0.00105	CcSEcCtD
Vilazodone—Decreased appetite—Estradiol—prostate cancer	0.000143	0.00105	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Estradiol—prostate cancer	0.000142	0.00104	CcSEcCtD
Vilazodone—Diarrhoea—Goserelin—prostate cancer	0.000142	0.00104	CcSEcCtD
Vilazodone—Connective tissue disorder—Capecitabine—prostate cancer	0.000142	0.00104	CcSEcCtD
Vilazodone—Fatigue—Estradiol—prostate cancer	0.000142	0.00104	CcSEcCtD
Vilazodone—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000141	0.00103	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.00014	0.00102	CcSEcCtD
Vilazodone—Eye disorder—Docetaxel—prostate cancer	0.000139	0.00102	CcSEcCtD
Vilazodone—Cardiac disorder—Docetaxel—prostate cancer	0.000138	0.00102	CcSEcCtD
Vilazodone—Paraesthesia—Mitoxantrone—prostate cancer	0.000138	0.00101	CcSEcCtD
Vilazodone—Dizziness—Goserelin—prostate cancer	0.000137	0.00101	CcSEcCtD
Vilazodone—Somnolence—Mitoxantrone—prostate cancer	0.000136	0.001	CcSEcCtD
Vilazodone—Dizziness—Conjugated Estrogens—prostate cancer	0.000136	0.000997	CcSEcCtD
Vilazodone—Feeling abnormal—Estradiol—prostate cancer	0.000136	0.000995	CcSEcCtD
Vilazodone—Convulsion—Etoposide—prostate cancer	0.000135	0.000993	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—prostate cancer	0.000135	0.000991	CcSEcCtD
Vilazodone—Eye disorder—Capecitabine—prostate cancer	0.000135	0.00099	CcSEcCtD
Vilazodone—Dyspepsia—Mitoxantrone—prostate cancer	0.000135	0.00099	CcSEcCtD
Vilazodone—Cardiac disorder—Capecitabine—prostate cancer	0.000134	0.000983	CcSEcCtD
Vilazodone—Decreased appetite—Mitoxantrone—prostate cancer	0.000133	0.000978	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—prostate cancer	0.000132	0.000972	CcSEcCtD
Vilazodone—Fatigue—Mitoxantrone—prostate cancer	0.000132	0.00097	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000132	0.000969	CcSEcCtD
Vilazodone—Vomiting—Goserelin—prostate cancer	0.000132	0.000968	CcSEcCtD
Vilazodone—Breast disorder—Epirubicin—prostate cancer	0.000131	0.000964	CcSEcCtD
Vilazodone—Vomiting—Conjugated Estrogens—prostate cancer	0.000131	0.000959	CcSEcCtD
Vilazodone—Mental disorder—Docetaxel—prostate cancer	0.000131	0.000959	CcSEcCtD
Vilazodone—Malnutrition—Docetaxel—prostate cancer	0.00013	0.000953	CcSEcCtD
Vilazodone—Hallucination—Prednisone—prostate cancer	0.000128	0.000939	CcSEcCtD
Vilazodone—Dysgeusia—Docetaxel—prostate cancer	0.000127	0.000933	CcSEcCtD
Vilazodone—Mental disorder—Capecitabine—prostate cancer	0.000127	0.000928	CcSEcCtD
Vilazodone—Connective tissue disorder—Prednisone—prostate cancer	0.000126	0.000927	CcSEcCtD
Vilazodone—Feeling abnormal—Mitoxantrone—prostate cancer	0.000126	0.000927	CcSEcCtD
Vilazodone—Malnutrition—Capecitabine—prostate cancer	0.000126	0.000922	CcSEcCtD
Vilazodone—Flatulence—Capecitabine—prostate cancer	0.000124	0.000909	CcSEcCtD
Vilazodone—Skin disorder—Etoposide—prostate cancer	0.000124	0.000909	CcSEcCtD
Vilazodone—Nausea—Goserelin—prostate cancer	0.000123	0.000904	CcSEcCtD
Vilazodone—Hyperhidrosis—Etoposide—prostate cancer	0.000123	0.000904	CcSEcCtD
Vilazodone—Dysgeusia—Capecitabine—prostate cancer	0.000123	0.000903	CcSEcCtD
Vilazodone—Nausea—Conjugated Estrogens—prostate cancer	0.000122	0.000896	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—prostate cancer	0.000122	0.000892	CcSEcCtD
Vilazodone—Eye disorder—Prednisone—prostate cancer	0.00012	0.000882	CcSEcCtD
Vilazodone—Vision blurred—Capecitabine—prostate cancer	0.000118	0.000869	CcSEcCtD
Vilazodone—Asthenia—Estradiol—prostate cancer	0.000118	0.000866	CcSEcCtD
Vilazodone—Tremor—Capecitabine—prostate cancer	0.000118	0.000864	CcSEcCtD
Vilazodone—Pollakiuria—Epirubicin—prostate cancer	0.000116	0.000852	CcSEcCtD
Vilazodone—Palpitations—Docetaxel—prostate cancer	0.000115	0.000842	CcSEcCtD
Vilazodone—Paraesthesia—Etoposide—prostate cancer	0.000115	0.00084	CcSEcCtD
Vilazodone—Somnolence—Etoposide—prostate cancer	0.000113	0.000832	CcSEcCtD
Vilazodone—Mental disorder—Prednisone—prostate cancer	0.000113	0.000827	CcSEcCtD
Vilazodone—Diarrhoea—Estradiol—prostate cancer	0.000113	0.000826	CcSEcCtD
Vilazodone—Convulsion—Docetaxel—prostate cancer	0.000113	0.000825	CcSEcCtD
Vilazodone—Malnutrition—Prednisone—prostate cancer	0.000112	0.000822	CcSEcCtD
Vilazodone—Palpitations—Capecitabine—prostate cancer	0.000111	0.000815	CcSEcCtD
Vilazodone—Decreased appetite—Etoposide—prostate cancer	0.000111	0.000813	CcSEcCtD
Vilazodone—Arthralgia—Docetaxel—prostate cancer	0.000111	0.000811	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Etoposide—prostate cancer	0.00011	0.000808	CcSEcCtD
Vilazodone—Asthenia—Mitoxantrone—prostate cancer	0.00011	0.000807	CcSEcCtD
Vilazodone—Fatigue—Etoposide—prostate cancer	0.00011	0.000807	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00011	0.000805	CcSEcCtD
Vilazodone—Dizziness—Estradiol—prostate cancer	0.000109	0.000798	CcSEcCtD
Vilazodone—Dry mouth—Docetaxel—prostate cancer	0.000108	0.000793	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—prostate cancer	0.000107	0.000788	CcSEcCtD
Vilazodone—Arthralgia—Capecitabine—prostate cancer	0.000107	0.000785	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000106	0.00078	CcSEcCtD
Vilazodone—Vision blurred—Prednisone—prostate cancer	0.000106	0.000774	CcSEcCtD
Vilazodone—Feeling abnormal—Etoposide—prostate cancer	0.000105	0.000771	CcSEcCtD
Vilazodone—Diarrhoea—Mitoxantrone—prostate cancer	0.000105	0.00077	CcSEcCtD
Vilazodone—Dry mouth—Capecitabine—prostate cancer	0.000105	0.000768	CcSEcCtD
Vilazodone—Vomiting—Estradiol—prostate cancer	0.000105	0.000767	CcSEcCtD
Vilazodone—Nervous system disorder—Docetaxel—prostate cancer	0.000104	0.000762	CcSEcCtD
Vilazodone—Skin disorder—Docetaxel—prostate cancer	0.000103	0.000755	CcSEcCtD
Vilazodone—Agitation—Prednisone—prostate cancer	0.000103	0.000755	CcSEcCtD
Vilazodone—Nervous system disorder—Capecitabine—prostate cancer	0.000101	0.000738	CcSEcCtD
Vilazodone—Skin disorder—Capecitabine—prostate cancer	9.97e-05	0.000731	CcSEcCtD
Vilazodone—Hyperhidrosis—Capecitabine—prostate cancer	9.92e-05	0.000728	CcSEcCtD
Vilazodone—Connective tissue disorder—Epirubicin—prostate cancer	9.89e-05	0.000725	CcSEcCtD
Vilazodone—Nausea—Estradiol—prostate cancer	9.77e-05	0.000717	CcSEcCtD
Vilazodone—Vomiting—Mitoxantrone—prostate cancer	9.75e-05	0.000715	CcSEcCtD
Vilazodone—Convulsion—Prednisone—prostate cancer	9.7e-05	0.000712	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Docetaxel—prostate cancer	9.66e-05	0.000708	CcSEcCtD
Vilazodone—Insomnia—Docetaxel—prostate cancer	9.59e-05	0.000703	CcSEcCtD
Vilazodone—Arthralgia—Prednisone—prostate cancer	9.53e-05	0.000699	CcSEcCtD
Vilazodone—Paraesthesia—Docetaxel—prostate cancer	9.52e-05	0.000698	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.47e-05	0.000695	CcSEcCtD
Vilazodone—Somnolence—Docetaxel—prostate cancer	9.42e-05	0.000691	CcSEcCtD
Vilazodone—Eye disorder—Epirubicin—prostate cancer	9.4e-05	0.00069	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Capecitabine—prostate cancer	9.35e-05	0.000686	CcSEcCtD
Vilazodone—Cardiac disorder—Epirubicin—prostate cancer	9.34e-05	0.000685	CcSEcCtD
Vilazodone—Dyspepsia—Docetaxel—prostate cancer	9.33e-05	0.000684	CcSEcCtD
Vilazodone—Insomnia—Capecitabine—prostate cancer	9.28e-05	0.000681	CcSEcCtD
Vilazodone—Paraesthesia—Capecitabine—prostate cancer	9.21e-05	0.000676	CcSEcCtD
Vilazodone—Decreased appetite—Docetaxel—prostate cancer	9.21e-05	0.000676	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Docetaxel—prostate cancer	9.15e-05	0.000671	CcSEcCtD
Vilazodone—Asthenia—Etoposide—prostate cancer	9.15e-05	0.000671	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—prostate cancer	9.15e-05	0.000671	CcSEcCtD
Vilazodone—Fatigue—Docetaxel—prostate cancer	9.14e-05	0.00067	CcSEcCtD
Vilazodone—Nausea—Mitoxantrone—prostate cancer	9.11e-05	0.000668	CcSEcCtD
Vilazodone—Dyspepsia—Capecitabine—prostate cancer	9.03e-05	0.000663	CcSEcCtD
Vilazodone—Nervous system disorder—Prednisone—prostate cancer	8.96e-05	0.000658	CcSEcCtD
Vilazodone—Decreased appetite—Capecitabine—prostate cancer	8.92e-05	0.000654	CcSEcCtD
Vilazodone—Skin disorder—Prednisone—prostate cancer	8.88e-05	0.000651	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Capecitabine—prostate cancer	8.86e-05	0.00065	CcSEcCtD
Vilazodone—Fatigue—Capecitabine—prostate cancer	8.85e-05	0.000649	CcSEcCtD
Vilazodone—Hyperhidrosis—Prednisone—prostate cancer	8.84e-05	0.000648	CcSEcCtD
Vilazodone—Mental disorder—Epirubicin—prostate cancer	8.81e-05	0.000647	CcSEcCtD
Vilazodone—Malnutrition—Epirubicin—prostate cancer	8.76e-05	0.000643	CcSEcCtD
Vilazodone—Feeling abnormal—Docetaxel—prostate cancer	8.73e-05	0.000641	CcSEcCtD
Vilazodone—Diarrhoea—Etoposide—prostate cancer	8.73e-05	0.00064	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—prostate cancer	8.7e-05	0.000638	CcSEcCtD
Vilazodone—Cardiac disorder—Doxorubicin—prostate cancer	8.64e-05	0.000634	CcSEcCtD
Vilazodone—Flatulence—Epirubicin—prostate cancer	8.63e-05	0.000633	CcSEcCtD
Vilazodone—Dysgeusia—Epirubicin—prostate cancer	8.58e-05	0.000629	CcSEcCtD
Vilazodone—Nervousness—Epirubicin—prostate cancer	8.51e-05	0.000624	CcSEcCtD
Vilazodone—Feeling abnormal—Capecitabine—prostate cancer	8.46e-05	0.00062	CcSEcCtD
Vilazodone—Dizziness—Etoposide—prostate cancer	8.43e-05	0.000619	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Prednisone—prostate cancer	8.33e-05	0.000611	CcSEcCtD
Vilazodone—Insomnia—Prednisone—prostate cancer	8.27e-05	0.000606	CcSEcCtD
Vilazodone—Vision blurred—Epirubicin—prostate cancer	8.25e-05	0.000606	CcSEcCtD
Vilazodone—Paraesthesia—Prednisone—prostate cancer	8.21e-05	0.000602	CcSEcCtD
Vilazodone—Mental disorder—Doxorubicin—prostate cancer	8.16e-05	0.000598	CcSEcCtD
Vilazodone—Vomiting—Etoposide—prostate cancer	8.11e-05	0.000595	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—prostate cancer	8.1e-05	0.000595	CcSEcCtD
Vilazodone—Agitation—Epirubicin—prostate cancer	8.05e-05	0.00059	CcSEcCtD
Vilazodone—Dyspepsia—Prednisone—prostate cancer	8.05e-05	0.00059	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—prostate cancer	7.99e-05	0.000586	CcSEcCtD
Vilazodone—Decreased appetite—Prednisone—prostate cancer	7.95e-05	0.000583	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—prostate cancer	7.94e-05	0.000582	CcSEcCtD
Vilazodone—Fatigue—Prednisone—prostate cancer	7.88e-05	0.000578	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—prostate cancer	7.87e-05	0.000577	CcSEcCtD
Vilazodone—Palpitations—Epirubicin—prostate cancer	7.74e-05	0.000568	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—prostate cancer	7.64e-05	0.00056	CcSEcCtD
Vilazodone—Asthenia—Docetaxel—prostate cancer	7.6e-05	0.000558	CcSEcCtD
Vilazodone—Convulsion—Epirubicin—prostate cancer	7.59e-05	0.000557	CcSEcCtD
Vilazodone—Nausea—Etoposide—prostate cancer	7.57e-05	0.000556	CcSEcCtD
Vilazodone—Feeling abnormal—Prednisone—prostate cancer	7.53e-05	0.000553	CcSEcCtD
Vilazodone—Arthralgia—Epirubicin—prostate cancer	7.46e-05	0.000547	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—prostate cancer	7.45e-05	0.000546	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.41e-05	0.000543	CcSEcCtD
Vilazodone—Asthenia—Capecitabine—prostate cancer	7.36e-05	0.00054	CcSEcCtD
Vilazodone—Dry mouth—Epirubicin—prostate cancer	7.29e-05	0.000535	CcSEcCtD
Vilazodone—Diarrhoea—Docetaxel—prostate cancer	7.25e-05	0.000532	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—prostate cancer	7.16e-05	0.000525	CcSEcCtD
Vilazodone—Convulsion—Doxorubicin—prostate cancer	7.02e-05	0.000515	CcSEcCtD
Vilazodone—Diarrhoea—Capecitabine—prostate cancer	7.02e-05	0.000515	CcSEcCtD
Vilazodone—Nervous system disorder—Epirubicin—prostate cancer	7.01e-05	0.000514	CcSEcCtD
Vilazodone—Dizziness—Docetaxel—prostate cancer	7.01e-05	0.000514	CcSEcCtD
Vilazodone—Skin disorder—Epirubicin—prostate cancer	6.94e-05	0.000509	CcSEcCtD
Vilazodone—Hyperhidrosis—Epirubicin—prostate cancer	6.91e-05	0.000507	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—prostate cancer	6.9e-05	0.000506	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.85e-05	0.000503	CcSEcCtD
Vilazodone—Dizziness—Capecitabine—prostate cancer	6.79e-05	0.000498	CcSEcCtD
Vilazodone—Dry mouth—Doxorubicin—prostate cancer	6.75e-05	0.000495	CcSEcCtD
Vilazodone—Vomiting—Docetaxel—prostate cancer	6.74e-05	0.000494	CcSEcCtD
Vilazodone—Asthenia—Prednisone—prostate cancer	6.56e-05	0.000481	CcSEcCtD
Vilazodone—Vomiting—Capecitabine—prostate cancer	6.52e-05	0.000479	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.51e-05	0.000478	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—prostate cancer	6.49e-05	0.000476	CcSEcCtD
Vilazodone—Insomnia—Epirubicin—prostate cancer	6.47e-05	0.000474	CcSEcCtD
Vilazodone—Skin disorder—Doxorubicin—prostate cancer	6.42e-05	0.000471	CcSEcCtD
Vilazodone—Paraesthesia—Epirubicin—prostate cancer	6.42e-05	0.000471	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—prostate cancer	6.39e-05	0.000469	CcSEcCtD
Vilazodone—Somnolence—Epirubicin—prostate cancer	6.35e-05	0.000466	CcSEcCtD
Vilazodone—Nausea—Docetaxel—prostate cancer	6.3e-05	0.000462	CcSEcCtD
Vilazodone—Dyspepsia—Epirubicin—prostate cancer	6.29e-05	0.000462	CcSEcCtD
Vilazodone—Diarrhoea—Prednisone—prostate cancer	6.25e-05	0.000459	CcSEcCtD
Vilazodone—Decreased appetite—Epirubicin—prostate cancer	6.21e-05	0.000456	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Epirubicin—prostate cancer	6.17e-05	0.000453	CcSEcCtD
Vilazodone—Fatigue—Epirubicin—prostate cancer	6.16e-05	0.000452	CcSEcCtD
Vilazodone—Nausea—Capecitabine—prostate cancer	6.09e-05	0.000447	CcSEcCtD
Vilazodone—Dizziness—Prednisone—prostate cancer	6.04e-05	0.000443	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—prostate cancer	6.03e-05	0.000442	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—prostate cancer	5.98e-05	0.000439	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—prostate cancer	5.94e-05	0.000436	CcSEcCtD
Vilazodone—Feeling abnormal—Epirubicin—prostate cancer	5.89e-05	0.000432	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—prostate cancer	5.88e-05	0.000431	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—prostate cancer	5.82e-05	0.000427	CcSEcCtD
Vilazodone—Vomiting—Prednisone—prostate cancer	5.81e-05	0.000426	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—prostate cancer	5.75e-05	0.000422	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.71e-05	0.000419	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—prostate cancer	5.7e-05	0.000418	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—prostate cancer	5.45e-05	0.0004	CcSEcCtD
Vilazodone—Nausea—Prednisone—prostate cancer	5.43e-05	0.000398	CcSEcCtD
Vilazodone—Asthenia—Epirubicin—prostate cancer	5.13e-05	0.000376	CcSEcCtD
Vilazodone—Diarrhoea—Epirubicin—prostate cancer	4.89e-05	0.000359	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—prostate cancer	4.75e-05	0.000348	CcSEcCtD
Vilazodone—Dizziness—Epirubicin—prostate cancer	4.73e-05	0.000347	CcSEcCtD
Vilazodone—Vomiting—Epirubicin—prostate cancer	4.55e-05	0.000333	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—prostate cancer	4.53e-05	0.000332	CcSEcCtD
Vilazodone—Dizziness—Doxorubicin—prostate cancer	4.37e-05	0.000321	CcSEcCtD
Vilazodone—Nausea—Epirubicin—prostate cancer	4.25e-05	0.000311	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—prostate cancer	4.21e-05	0.000308	CcSEcCtD
Vilazodone—Nausea—Doxorubicin—prostate cancer	3.93e-05	0.000288	CcSEcCtD
Vilazodone—HTR1A—Signaling Pathways—IGF1R—prostate cancer	6.49e-06	7.28e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CB—prostate cancer	6.47e-06	7.25e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL8—prostate cancer	6.46e-06	7.25e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—JAK2—prostate cancer	6.43e-06	7.21e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—prostate cancer	6.41e-06	7.18e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LDHB—prostate cancer	6.38e-06	7.15e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGF10—prostate cancer	6.37e-06	7.14e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ADRB2—prostate cancer	6.3e-06	7.07e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HPGDS—prostate cancer	6.29e-06	7.05e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP3A5—prostate cancer	6.26e-06	7.02e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2C19—prostate cancer	6.25e-06	7e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LPL—prostate cancer	6.22e-06	6.98e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—JAK2—prostate cancer	6.22e-06	6.97e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAP2K1—prostate cancer	6.19e-06	6.94e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—IL2—prostate cancer	6.18e-06	6.93e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PDGFRB—prostate cancer	6.17e-06	6.92e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CD—prostate cancer	6.15e-06	6.9e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VAV3—prostate cancer	6.15e-06	6.89e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CB—prostate cancer	6.11e-06	6.85e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ACHE—prostate cancer	6.1e-06	6.84e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTT1—prostate cancer	6.1e-06	6.84e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFBR2—prostate cancer	6.06e-06	6.79e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA3—prostate cancer	6.05e-06	6.78e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PDHA1—prostate cancer	6.05e-06	6.78e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TCN2—prostate cancer	6.05e-06	6.78e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—UCP3—prostate cancer	6.05e-06	6.78e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2A6—prostate cancer	6.03e-06	6.76e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ITGB3—prostate cancer	6.01e-06	6.74e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ITPR1—prostate cancer	5.96e-06	6.68e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CB—prostate cancer	5.9e-06	6.62e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—prostate cancer	5.87e-06	6.58e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKR1C3—prostate cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PRKACB—prostate cancer	5.83e-06	6.54e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB3—prostate cancer	5.83e-06	6.54e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGFR2—prostate cancer	5.82e-06	6.53e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP17A1—prostate cancer	5.77e-06	6.47e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.77e-06	6.47e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.77e-06	6.47e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1R—prostate cancer	5.7e-06	6.39e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—prostate cancer	5.67e-06	6.36e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—JAK2—prostate cancer	5.65e-06	6.33e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2—prostate cancer	5.61e-06	6.29e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TERT—prostate cancer	5.59e-06	6.27e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTEN—prostate cancer	5.59e-06	6.27e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TBXAS1—prostate cancer	5.53e-06	6.2e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA4—prostate cancer	5.53e-06	6.2e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOA2—prostate cancer	5.5e-06	6.17e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LPL—prostate cancer	5.46e-06	6.13e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2—prostate cancer	5.42e-06	6.08e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PDGFRB—prostate cancer	5.42e-06	6.07e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA2—prostate cancer	5.39e-06	6.04e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CB—prostate cancer	5.36e-06	6.01e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—prostate cancer	5.34e-06	5.99e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—EP300—prostate cancer	5.33e-06	5.98e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCG5—prostate cancer	5.32e-06	5.97e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SULT1A1—prostate cancer	5.32e-06	5.97e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ITGB3—prostate cancer	5.28e-06	5.92e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC5A5—prostate cancer	5.25e-06	5.88e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LEP—prostate cancer	5.22e-06	5.85e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA1—prostate cancer	5.2e-06	5.83e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CAV1—prostate cancer	5.17e-06	5.8e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—prostate cancer	5.15e-06	5.78e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HSD3B2—prostate cancer	5.14e-06	5.76e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NAT2—prostate cancer	5.14e-06	5.76e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTO1—prostate cancer	5.14e-06	5.76e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2E1—prostate cancer	5.12e-06	5.75e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB3—prostate cancer	5.12e-06	5.74e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGFR2—prostate cancer	5.11e-06	5.73e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KDR—prostate cancer	5.11e-06	5.73e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NQO1—prostate cancer	5.07e-06	5.68e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TH—prostate cancer	4.99e-06	5.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ESR1—prostate cancer	4.98e-06	5.58e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP3A4—prostate cancer	4.94e-06	5.54e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PLCB2—prostate cancer	4.93e-06	5.53e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LRP2—prostate cancer	4.93e-06	5.53e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.93e-06	5.53e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2—prostate cancer	4.92e-06	5.52e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TERT—prostate cancer	4.91e-06	5.5e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—BAD—prostate cancer	4.86e-06	5.45e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1B1—prostate cancer	4.86e-06	5.45e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—P4HB—prostate cancer	4.83e-06	5.42e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CG—prostate cancer	4.71e-06	5.28e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APC—prostate cancer	4.71e-06	5.28e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GGT1—prostate cancer	4.7e-06	5.28e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.7e-06	5.27e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—prostate cancer	4.69e-06	5.26e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGF—prostate cancer	4.65e-06	5.22e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IRS1—prostate cancer	4.65e-06	5.22e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOA1—prostate cancer	4.63e-06	5.2e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.58e-06	5.14e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LEP—prostate cancer	4.58e-06	5.14e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP19A1—prostate cancer	4.57e-06	5.12e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CAV1—prostate cancer	4.54e-06	5.09e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GSK3B—prostate cancer	4.52e-06	5.07e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MED12—prostate cancer	4.51e-06	5.05e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KDR—prostate cancer	4.49e-06	5.03e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GNG5—prostate cancer	4.47e-06	5.01e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—INS—prostate cancer	4.46e-06	5e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—RXRA—prostate cancer	4.41e-06	4.94e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ESR1—prostate cancer	4.37e-06	4.9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CREBBP—prostate cancer	4.37e-06	4.89e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1—prostate cancer	4.31e-06	4.83e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA3—prostate cancer	4.31e-06	4.83e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—prostate cancer	4.29e-06	4.81e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—BAD—prostate cancer	4.27e-06	4.79e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—COMT—prostate cancer	4.25e-06	4.76e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTP1—prostate cancer	4.23e-06	4.74e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	4.17e-06	4.67e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ITPR1—prostate cancer	4.16e-06	4.66e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	4.14e-06	4.64e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APC—prostate cancer	4.13e-06	4.64e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CG—prostate cancer	4.13e-06	4.64e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HPGDS—prostate cancer	4.11e-06	4.61e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	4.1e-06	4.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	4.09e-06	4.59e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGF—prostate cancer	4.09e-06	4.58e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IRS1—prostate cancer	4.09e-06	4.58e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.08e-06	4.58e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—KRAS—prostate cancer	4.05e-06	4.54e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—prostate cancer	3.99e-06	4.47e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ACHE—prostate cancer	3.99e-06	4.47e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GSK3B—prostate cancer	3.97e-06	4.45e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGF2—prostate cancer	3.96e-06	4.44e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CA—prostate cancer	3.94e-06	4.42e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.94e-06	4.42e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMS—prostate cancer	3.93e-06	4.41e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—INS—prostate cancer	3.91e-06	4.39e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOS3—prostate cancer	3.91e-06	4.38e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—prostate cancer	3.88e-06	4.35e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.83e-06	4.3e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CREBBP—prostate cancer	3.83e-06	4.3e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PRKACB—prostate cancer	3.81e-06	4.28e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LPL—prostate cancer	3.81e-06	4.27e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JAK2—prostate cancer	3.8e-06	4.26e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1—prostate cancer	3.78e-06	4.24e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.77e-06	4.23e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—prostate cancer	3.77e-06	4.22e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	3.72e-06	4.17e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MDM2—prostate cancer	3.71e-06	4.16e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.68e-06	4.13e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAP2K1—prostate cancer	3.66e-06	4.1e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB2—prostate cancer	3.66e-06	4.1e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ERCC2—prostate cancer	3.65e-06	4.09e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CD—prostate cancer	3.63e-06	4.07e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	3.61e-06	4.05e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	3.6e-06	4.04e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA2—prostate cancer	3.6e-06	4.03e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SERPINE1—prostate cancer	3.59e-06	4.03e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KRAS—prostate cancer	3.56e-06	3.99e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGF2—prostate cancer	3.48e-06	3.9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—prostate cancer	3.47e-06	3.89e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTHFR—prostate cancer	3.43e-06	3.85e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOS3—prostate cancer	3.43e-06	3.85e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.43e-06	3.85e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	3.39e-06	3.8e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARA—prostate cancer	3.37e-06	3.78e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.35e-06	3.76e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	3.35e-06	3.76e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JAK2—prostate cancer	3.33e-06	3.74e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CASP3—prostate cancer	3.32e-06	3.72e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2—prostate cancer	3.31e-06	3.71e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NQO1—prostate cancer	3.31e-06	3.71e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—prostate cancer	3.3e-06	3.7e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	3.27e-06	3.67e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TH—prostate cancer	3.26e-06	3.66e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MDM2—prostate cancer	3.26e-06	3.65e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—prostate cancer	3.23e-06	3.62e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AKT1—prostate cancer	3.22e-06	3.61e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB2—prostate cancer	3.21e-06	3.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	3.2e-06	3.59e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.18e-06	3.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CB—prostate cancer	3.17e-06	3.55e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CAV1—prostate cancer	3.17e-06	3.55e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—prostate cancer	3.14e-06	3.52e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	3.12e-06	3.5e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTEN—prostate cancer	3.12e-06	3.5e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GGT1—prostate cancer	3.08e-06	3.45e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—prostate cancer	3.04e-06	3.41e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT1—prostate cancer	3.04e-06	3.41e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA1—prostate cancer	3.03e-06	3.4e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.99e-06	3.35e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EP300—prostate cancer	2.97e-06	3.33e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1B—prostate cancer	2.97e-06	3.33e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT1—prostate cancer	2.94e-06	3.3e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASP3—prostate cancer	2.91e-06	3.27e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2—prostate cancer	2.91e-06	3.26e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—prostate cancer	2.89e-06	3.25e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SRC—prostate cancer	2.89e-06	3.24e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.88e-06	3.23e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—RXRA—prostate cancer	2.88e-06	3.23e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—prostate cancer	2.84e-06	3.18e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—prostate cancer	2.82e-06	3.16e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CTNNB1—prostate cancer	2.81e-06	3.15e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STAT3—prostate cancer	2.79e-06	3.13e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—COMT—prostate cancer	2.78e-06	3.11e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTP1—prostate cancer	2.76e-06	3.1e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—prostate cancer	2.75e-06	3.09e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1A—prostate cancer	2.74e-06	3.08e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTEN—prostate cancer	2.74e-06	3.07e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—INS—prostate cancer	2.73e-06	3.06e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ITPR1—prostate cancer	2.72e-06	3.05e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CREBBP—prostate cancer	2.67e-06	3e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT1—prostate cancer	2.67e-06	2.99e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EP300—prostate cancer	2.61e-06	2.93e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—prostate cancer	2.59e-06	2.9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—prostate cancer	2.58e-06	2.9e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMS—prostate cancer	2.57e-06	2.88e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—prostate cancer	2.54e-06	2.85e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SRC—prostate cancer	2.54e-06	2.85e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.53e-06	2.84e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—prostate cancer	2.53e-06	2.84e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LPL—prostate cancer	2.49e-06	2.79e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—prostate cancer	2.47e-06	2.77e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT3—prostate cancer	2.45e-06	2.74e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.41e-06	2.7e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NOS3—prostate cancer	2.39e-06	2.68e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KRAS—prostate cancer	2.39e-06	2.68e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ERCC2—prostate cancer	2.39e-06	2.68e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—prostate cancer	2.27e-06	2.55e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—prostate cancer	2.27e-06	2.54e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTHFR—prostate cancer	2.24e-06	2.52e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—prostate cancer	2.22e-06	2.49e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.21e-06	2.48e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARA—prostate cancer	2.2e-06	2.47e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	2.2e-06	2.47e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—prostate cancer	2.19e-06	2.45e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—prostate cancer	2.13e-06	2.39e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KRAS—prostate cancer	2.1e-06	2.36e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CAV1—prostate cancer	2.07e-06	2.32e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—prostate cancer	1.95e-06	2.18e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.93e-06	2.17e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTEN—prostate cancer	1.91e-06	2.14e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—prostate cancer	1.87e-06	2.09e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—EP300—prostate cancer	1.82e-06	2.04e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT1—prostate cancer	1.8e-06	2.01e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—INS—prostate cancer	1.78e-06	2e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CREBBP—prostate cancer	1.75e-06	1.96e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—prostate cancer	1.71e-06	1.92e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.66e-06	1.86e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT1—prostate cancer	1.58e-06	1.77e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NOS3—prostate cancer	1.57e-06	1.75e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.44e-06	1.62e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—prostate cancer	1.43e-06	1.61e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.35e-06	1.51e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTEN—prostate cancer	1.25e-06	1.4e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—EP300—prostate cancer	1.19e-06	1.33e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKT1—prostate cancer	1.1e-06	1.23e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.81e-07	9.87e-06	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKT1—prostate cancer	7.19e-07	8.07e-06	CbGpPWpGaD
